Discovery of 3,5-diamino-1,2,4-triazole ureas as potent anaplastic lymphoma kinase inhibitors

ACS Medicinal Chemistry Letters

Volumn 2, Issue 5, 2011, Pages 379-384

  Deng, Xianming ^a,c   Wang, Jinhua ^a,c   Zhang, Jianming ^a,c   Sim, Taebo ^a,c   Kim, Nam Doo ^b   Sasaki, Takaaki ^c   Luther, William ^c   George, Rani E ^c   Jänne, Pasi A ^c   Gray, Nathanael S ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Yonsei University   (South Korea)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

3,5 diamino 1,2,4 triazole urea; ALK

Indexed keywords

3,5 DIAMINO 1,2,4 TRIAZOLE UREA; ADENOSINE KINASE INHIBITOR; ADENOSINE TRIPHOSPHATE; ANAPLASTIC LYMPHOMA KINASE; GUANAZOLE; NUCLEOPHOSMIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURGERY; CANCER THERAPY; CYTOTOXICITY; ENZYME INHIBITION; INHIBITION KINETICS; LARGE CELL LYMPHOMA; LYMPHOMA CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 79956148583     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200002a     Document Type: Article

References (27)

1. Morris, S. W.; Kirstein, M. N.; Valentine, M. B.; Dittmer, K. G.; Shapiro, D. N.; Saltman, D. L.; Look, A. T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 1994, 263, 1281-1284 (Pubitemid 24107549)
2. Li, R.; Morris, S. W. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy Med. Res. Rev. 2008, 28, 372-412 (Pubitemid 351590540)
3. Chiarle, R.; Voena, C.; Ambrogio, C.; Piva, R.; Inghirami, G. The anaplastic lymphoma kinase in the pathogenesis of cancer Nat. Rev. Cancer 2008, 8, 11-23
4. Soda, M.; Choi, Y. L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; ManoH., H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 2007, 448, 561-566 (Pubitemid 47206930)
5. Koivunen, J. P.; Mermel, C.; Zejnullahu, K.; Murphy, C.; Lifshits, E.; Holmes, A. J.; Choi, H. G.; Kim, J.; ChiangD., D.; ThomasR., R.; Lee, J.; RichardsW. G., W. G.; Sugarbaker, D. J.; Ducko, C.; Lindeman, N.; MarcouxJ. P., J. P.; Engelman, J. A.; Gray, N. S.; Lee, C.; MeyersonM., M.; Janne, P. A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer Clin. Cancer Res. 2008, 14, 4275-4283
6. Griffin, C. A.; Hawkins, A. L.; Dvorak, C.; Henkle, C.; Ellingham, T.; Perlman, E. J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors Cancer Res. 1999, 59, 2776-2780 (Pubitemid 29283106)
7. Cook, J. R.; Dehner, L. P.; Collins, M. H.; Ma, Z.; Morris, S. W.; Coffin, C. M.; Hill, D. A. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: A comparative immunohistochemical study Am. J. Surg. Pathol. 2001, 25, 1364-1371 (Pubitemid 33022051)
8. Gascoyne, R. D.; Lamant, L.; Martin-Subero, J. I.; Lestou, V. S.; Harris, N. L.; Muller-Hermelink, H. K.; Seymour, J. F.; Campbell, L. J.; Horsman, D. E.; Auvigne, I.; Espinos, E.; Siebert, R.; Delsol, G. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases Blood 2003, 102, 2568-2573 (Pubitemid 37193597)
9. Mosse, Y. P.; Wood, A.; Maris, J. M. Inhibition of ALK signaling for cancer therapy Clin. Cancer Res. 2009, 15, 5609-5614
10. George, R. E.; Sanda, T.; Hanna, M.; FrohlingS., S.; Luther, W., II; Zhang, J.; AhnY., Y.; ZhouW., W.; LondonW. B., W. B.; McGradyP., P.; XueL., L.; ZozulyaS., S.; GregorV. E., V. E.; WebbT. R., T. R.; GrayN. S., N. S.; GillilandD, D. G.; DillerL., L.; Greulich, H.; Morris, S. W.; Meyerson, M.; Look, A. T. Activating mutations in ALK provide a therapeutic target in neuroblastoma Nature 2008, 455, 975-978
11. Galkin, A. V.; Melnick, J. S.; Kim, S.; Hood, T. L.; Li, N.; Li, L.; Xia, G.; Steensma, R.; Chopiuk, G.; Jiang, J.; WanY., Y.; Ding, P.; Liu, Y.; Sun, F.; Schultz, P. G.; Gray, N. S.; Warmuth, M. Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 270-275 (Pubitemid 46068021)
12. McDermott, U.; Iafrate, A. J.; Gray, N. S.; Shioda, T.; Classon, M.; Maheswaran, S.; Zhou, W.; Choi, H. G.; Smith, S. L.; Dowell, L.; Ulkus, L. E.; Kuhlmann, G.; Greninger, P.; Christensen, J. G.; Haber, D. A.; Settleman, J. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors Cancer Res. 2008, 68, 3389-3395
13. Chen, Z.; Sasaki, T.; Tan, X.; Carretero, J.; Shimamura, T.; Li, D.; Xu, C.; Wang, Y.; Aldelmant, G. O.; Capelletti, M.; Lee, H. J.; Rodig, S. J.; Borgman, C. L.; Park, S. I.; Kim, H. R.; Padera, R. F., Jr.; Marto, J.; Gray, N.; Kung, A. L.; Shapiro, G. I.; Janne, P. A.; Wong, K. K. Inhibition of ALK, PI3K/MEK and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene Cancer Res. 2010, 70, 9827-9836
14. Cheng, M.; Ott, G. R. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma Anticancer Agents Med. Chem. 2010, 10, 236-249
15. Kwak, E. L.; Sasaki, T.; Tan, X.; Carretero, J.; Shimamura, T.; Li, D.; Xu, C.; Wang, Y.; Aldelmant, G. O.; Capelletti, M.; Lee, H. J.; Rodig, S. J.; Borgman, C. L.; Park, S. I.; Kim, H. R.; Padera, R. F., Jr.; Marto, J.; Gray, N.; Kung, A. L.; Shapiro, G. I.; Janne, P. A.; Wong, K. K. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N. Engl. J. Med. 2010, 363, 1693-1703
16. Butrynski, J. E.; D'Adamo, D. R.; Hornick, J. L.; Cin, P. D.; Antonescu, C. R.; Jhanwar, S. C.; Ladanyi, M.; Capelletti, M.; Rodig, S. J.; Ramaiya, N.; Kwak, E. L.; Clark, J. W.; Wilner, K. D.; Christensen, J. G.; Jänne, P. A.; Maki, R. G.; Demetri, G. D.; Shapiro, G. I. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor N. Engl. J. Med. 2010, 363, 1727-1733
17. Sasaki, T.; Okuda, K.; Zheng, W.; Butrynski, J.; Capelletti, M.; Wang, L.; Gray, N. S.; Wilner, K.; Christensen, J. G.; Demetri, G.; Shapiro, G. I.; Rodig, S. J.; Eck, M. J.; Jänne, P. A. The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers Cancer Res. 2010, 70, 10038-10043
18. Choi, Y. L.; Soda, M.; Yamashita, Y.; Ueno, T.; Takashima, J.; Nakajima, T.; Yatabe, Y; Takeuchi, K.; Hamada, T.; Haruta, H.; Ishikawa, Y.; Kimura, H.; Mitsudomi, T.; Tanio, Y.; Mano, H. ALK Lung Cancer Study Group. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors N. Engl. J. Med. 2010, 363, 1734-1739
19. Lee, C. C.; Jia, Y.; Li, N.; Sun, X.; Ng, K.; Ambing, E.; Gao, M. Y.; Hua, S.; Chen, C.; Kim, S.; Michellys, P. Y.; Lesley, S. A.; Harris, J. L.; Spraggon, G. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain Biochem. J. 2010, 430, 425-437
20. Bossi, R. T.; Saccardo, M. B.; Ardini, E.; Menichincheri, M.; Rusconi, L.; Magnaghi, P.; Orsini, P.; Avanzi, N.; Borgia, A. L.; Nesi, M.; Bandiera, T.; Fogliatto, G.; Bertrand, J. A. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors Biochemistry 2010, 49, 6813-6825
21. Webb, T. R.; Slavish, J.; George, R. E.; Look, A. T.; Xue, L.; Jiang, Q.; Cui, X.; Rentrop, W. B.; Morris, S. W. Anaplastic lymphoma kinase: Role in cancer pathogenesis and small-molecule inhibitor development for therapy Expert Rev. Anticancer Ther. 2009, 9, 331-356
22. Lin, R.; Connolly, P. J.; Huang, S.; Wetter, S. K.; Lu, Y.; Murray, W. V.; Emanuel, S. L.; Gruninger, R. H.; Fuentes-Pesquera, A. R.; Rugg, C. A.; Middleton, S. A.; Jolliffe, L. K. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: Synthesis and evaluation of biological activities J. Med. Chem. 2005, 48, 4208-4211 (Pubitemid 40884921)
23. Christensen, J. G.; Zou, H. Y.; Arango, M. E.; Li, Q.; Lee, J. H.; McDonnell, S. R.; Yamazaki, S.; Alton, G. R.; Mroczkowski, B.; Los, G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Mol. Cancer Ther. 2007, 6, 3314-3322
24. Kothe, M.; Kohls, D.; Low, S.; Coli, R.; Rennie, G. R.; Feru, F.; Kuhn, C.; Ding, Y. H. Selectivity-determining residues in Plk1 Chem. Biol. Drug Des. 2007, 70, 540-546 (Pubitemid 350150876)
25. Glide, version 3.5. http://www.schrodinger.com.
26. Sabbatini, P.; Korenchuk, S.; Rowand, J. L.; Groy, A.; Liu, Q.; Leperi, D.; Atkins, C.; Dumble, M.; Yang, J.; Anderson, K.; Kruger, R. G.; Gontarek, R. R.; Maksimchuk, K. R.; Suravajjala, S.; Lapierre, R. R.; Shotwell, J. B.; Wilson, J. W.; Chamberlain, S. D.; Rabindran, S. K.; Kumar, R. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers Mol. Cancer Ther. 2009, 8, 2811-2820
27. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132